Positive LidERA? Hidden risks beneath the SERD surface
- Amit Roy
- May 18
- 1 min read
Our latest detailed adjuvant SERDs analsyis reveals a potential mispricing emerging between Roche and AstraZeneca, with the market potentially extrapolating lidERA into a broader commercial opportunity than is warranted, while underappreciating more practice-aligned pathways elsewhere. The core debate is whether investors should be underwriting a broad SERD backbone in early breast cancer today, or positioning for a narrower outcome with a different catalyst path into 2027 that could shift relative value across the group.
Key questions we address include:
What does the lidERA adjuvant SERD dataset actually establish in terms of clinical positioning within early breast cancer?
Is the market over-extrapolating early efficacy signals into broad commercial adoption across early breast cancer?
Where is the true clinical and commercial entry point for next-generation SERDs in the adjuvant setting?
How should investors frame the relative importance of emerging trial designs that align with current treatment paradigms?
Are current valuations appropriately reflecting probability-weighted outcomes across Roche, AstraZeneca, and the broader SERD class into upcoming catalysts?
Comments